KR102483016B1 - ＦｃＲｎ 항체 및 이의 사용 방법 - Google Patents

ＦｃＲｎ 항체 및 이의 사용 방법 Download PDF

Info

Publication number
KR102483016B1
KR102483016B1 KR1020177024165A KR20177024165A KR102483016B1 KR 102483016 B1 KR102483016 B1 KR 102483016B1 KR 1020177024165 A KR1020177024165 A KR 1020177024165A KR 20177024165 A KR20177024165 A KR 20177024165A KR 102483016 B1 KR102483016 B1 KR 102483016B1
Authority
KR
South Korea
Prior art keywords
cdr
seq
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177024165A
Other languages
English (en)
Korean (ko)
Other versions
KR20170109020A (ko
Inventor
매럴린 커리
데이빗 제이. 킹
레오나 이. 링
제임스 3세 미도르
슈카리타 로이
앤서니 매닝
Original Assignee
모멘타 파머슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모멘타 파머슈티컬스 인코포레이티드 filed Critical 모멘타 파머슈티컬스 인코포레이티드
Priority to KR1020227045647A priority Critical patent/KR102792441B1/ko
Publication of KR20170109020A publication Critical patent/KR20170109020A/ko
Application granted granted Critical
Publication of KR102483016B1 publication Critical patent/KR102483016B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
KR1020177024165A 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법 Active KR102483016B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227045647A KR102792441B1 (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562110071P 2015-01-30 2015-01-30
US62/110,071 2015-01-30
US201562258082P 2015-11-20 2015-11-20
US62/258,082 2015-11-20
PCT/US2016/015720 WO2016123521A2 (en) 2015-01-30 2016-01-29 Fcrn antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045647A Division KR102792441B1 (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20170109020A KR20170109020A (ko) 2017-09-27
KR102483016B1 true KR102483016B1 (ko) 2023-01-03

Family

ID=56544538

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020177024165A Active KR102483016B1 (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법
KR1020257010788A Pending KR20250052465A (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법
KR1020227045647A Active KR102792441B1 (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257010788A Pending KR20250052465A (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법
KR1020227045647A Active KR102792441B1 (ko) 2015-01-30 2016-01-29 ＦｃＲｎ 항체 및 이의 사용 방법

Country Status (21)

Country Link
US (3) US10676526B2 (cg-RX-API-DMAC7.html)
EP (2) EP4286011A3 (cg-RX-API-DMAC7.html)
JP (2) JP6853178B2 (cg-RX-API-DMAC7.html)
KR (3) KR102483016B1 (cg-RX-API-DMAC7.html)
CN (13) CN118667014A (cg-RX-API-DMAC7.html)
AU (2) AU2016211280B2 (cg-RX-API-DMAC7.html)
DK (1) DK3250610T3 (cg-RX-API-DMAC7.html)
ES (1) ES2962824T3 (cg-RX-API-DMAC7.html)
FI (1) FI3250610T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231399T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063778T2 (cg-RX-API-DMAC7.html)
IL (1) IL252837B (cg-RX-API-DMAC7.html)
LT (1) LT3250610T (cg-RX-API-DMAC7.html)
NZ (1) NZ772383A (cg-RX-API-DMAC7.html)
PL (1) PL3250610T3 (cg-RX-API-DMAC7.html)
PT (1) PT3250610T (cg-RX-API-DMAC7.html)
RS (1) RS64768B1 (cg-RX-API-DMAC7.html)
SG (2) SG10202007232WA (cg-RX-API-DMAC7.html)
SI (1) SI3250610T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300365T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016123521A2 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014369999B2 (en) 2013-12-24 2019-12-12 The Board Of Regents Of The University Of Texas System FcRn antagonists and methods of use
RU2714153C2 (ru) * 2014-06-12 2020-02-12 Ф. Хоффманн-Ля Рош Аг СПОСОБ ОТБОРА АНТИТЕЛ С МОДИФИЦИРОВАННЫМ ВЗАИМОДЕЙСТВИЕМ С FcRn
CN118667014A (zh) 2015-01-30 2024-09-20 动量制药公司 Fcrn抗体及其使用方法
EP4282487A3 (en) * 2016-07-29 2024-02-14 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
RU2020100880A (ru) * 2017-06-15 2021-07-15 Юсб Биофарма Срл Способ лечения иммунной тромбоцитопении
AU2018380979B2 (en) 2017-12-08 2023-07-20 argenx BV Use of FcRn antagonists for treatment of generalized myasthenia gravis
SG11202005021PA (en) * 2017-12-13 2020-07-29 Momenta Pharmaceuticals Inc Fcrn antibodies and methods of use thereof
BR112020025001A2 (pt) 2018-06-08 2021-03-23 Argenx Bvba composições e métodos para o tratamento da trombocitopenia imune
CA3106669A1 (en) * 2018-07-20 2020-01-30 Momenta Pharmaceuticals, Inc. Compositions of fcrn antibodies and methods of use thereof
MX2021000788A (es) * 2018-07-20 2021-07-21 Momenta Pharmaceuticals Inc Composiciones de anticuerpos del receptor de fc (fcrn).
EP3866933A1 (en) 2018-10-16 2021-08-25 UCB Biopharma SRL Method for the treatment of myasthenia gravis
CN114126647A (zh) 2019-06-07 2022-03-01 阿尔金克斯有限公司 适用于皮下施用的FcRn抑制剂的药物制剂
JP2022542430A (ja) * 2019-08-01 2022-10-03 ヤンセン バイオテツク，インコーポレーテツド Ｆｃｒｎ抗体およびその使用の方法
EP4061486A1 (en) * 2019-11-19 2022-09-28 Immunovant Sciences GmbH Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
TW202140552A (zh) 2020-01-08 2021-11-01 比利時商阿根思公司 用於治療天皰瘡病症的方法
US20220144946A1 (en) * 2020-11-06 2022-05-12 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
CN114410643B (zh) * 2021-02-02 2024-08-02 百奥赛图(北京)医药科技股份有限公司 FcRn基因人源化的非人动物及其构建方法和应用
KR20240036076A (ko) * 2021-08-13 2024-03-19 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 Fcrn을 특이적으로 인식하는 항체 및 이의 용도
CN116234827A (zh) * 2021-09-03 2023-06-06 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
KR20250018382A (ko) 2022-05-30 2025-02-05 한올바이오파마주식회사 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편
AU2023291783A1 (en) 2022-06-15 2024-12-12 argenx BV Fcrn binding molecules and methods of use
IL322228A (en) 2023-02-04 2025-09-01 Momenta Pharmaceuticals Inc Compositions and methods for treating hemolytic disease of the fetus and newborn
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1475101B1 (en) 2002-02-14 2010-10-27 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
JP2007501847A (ja) * 2003-08-08 2007-02-01 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
AR054233A1 (es) 2005-03-08 2007-06-13 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos igg2
WO2007087289A2 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
CN101421297A (zh) * 2006-02-17 2009-04-29 森托尼克斯制药有限公司 阻断lgG对FcRn的结合的肽
EP2004690A2 (en) * 2006-03-13 2008-12-24 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
TWI593423B (zh) * 2008-04-25 2017-08-01 戴埃克斯有限公司 Ｆｃ受體結合蛋白
JP5683581B2 (ja) * 2009-06-30 2015-03-11 リサーチ ディベロップメント ファウンデーション 免疫グロブリンＦｃポリペプチド
SG10201604493TA (en) * 2011-06-02 2016-07-28 Dyax Corp Fc RECEPTOR BINDING PROTEINS
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
EP2934587A4 (en) 2012-12-18 2016-08-03 Merck Sharp & Dohme Liquid formulations for an anti-TNF-alpha-antibody
EP3719122A1 (en) 2013-05-02 2020-10-07 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
CN118667014A (zh) 2015-01-30 2024-09-20 动量制药公司 Fcrn抗体及其使用方法
AU2016230827B2 (en) * 2015-03-09 2021-10-28 argenx BV Methods of reducing serum levels of fc-containing agents using fcrn antagonists
ES2956662T3 (es) 2015-05-12 2023-12-26 Syntimmune Inc Anticuerpos anti-FcRn humanizados con afinidad madurada
EP4282487A3 (en) * 2016-07-29 2024-02-14 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
AU2018380979B2 (en) 2017-12-08 2023-07-20 argenx BV Use of FcRn antagonists for treatment of generalized myasthenia gravis
SG11202005021PA (en) 2017-12-13 2020-07-29 Momenta Pharmaceuticals Inc Fcrn antibodies and methods of use thereof
MX2021000788A (es) 2018-07-20 2021-07-21 Momenta Pharmaceuticals Inc Composiciones de anticuerpos del receptor de fc (fcrn).
CA3106669A1 (en) 2018-07-20 2020-01-30 Momenta Pharmaceuticals, Inc. Compositions of fcrn antibodies and methods of use thereof

Also Published As

Publication number Publication date
CN107567460B (zh) 2021-04-23
CN118652337A (zh) 2024-09-17
CN118667010A (zh) 2024-09-20
CN107567460A (zh) 2018-01-09
CN118667009A (zh) 2024-09-20
EP3250610A2 (en) 2017-12-06
PT3250610T (pt) 2023-11-13
AU2022201145B2 (en) 2024-11-14
JP2021061854A (ja) 2021-04-22
ES2962824T3 (es) 2024-03-21
FI3250610T3 (fi) 2023-11-01
HRP20231399T1 (hr) 2024-02-16
HUE063778T2 (hu) 2024-01-28
US20180016334A1 (en) 2018-01-18
JP2018504907A (ja) 2018-02-22
SG10202007232WA (en) 2020-09-29
PL3250610T3 (pl) 2024-01-29
EP3250610A4 (en) 2018-08-22
AU2016211280B2 (en) 2021-11-25
EP4286011A2 (en) 2023-12-06
IL252837B (en) 2021-10-31
EP3250610B1 (en) 2023-08-09
KR102792441B1 (ko) 2025-04-08
AU2022201145A1 (en) 2022-03-17
US11732047B2 (en) 2023-08-22
KR20250052465A (ko) 2025-04-18
US20200299382A1 (en) 2020-09-24
CA2972822A1 (en) 2016-08-04
CN118667014A (zh) 2024-09-20
WO2016123521A3 (en) 2016-09-22
CN118667013A (zh) 2024-09-20
WO2016123521A2 (en) 2016-08-04
IL252837A0 (en) 2017-08-31
CN113384693A (zh) 2021-09-14
RS64768B1 (sr) 2023-11-30
CN118667015A (zh) 2024-09-20
CN118638229A (zh) 2024-09-13
NZ733097A (en) 2024-07-05
US10676526B2 (en) 2020-06-09
CN118667011A (zh) 2024-09-20
BR112017015287A2 (pt) 2018-01-16
LT3250610T (lt) 2023-09-25
NZ772383A (en) 2024-11-29
AU2016211280A1 (en) 2017-07-13
JP6853178B2 (ja) 2021-03-31
SG11201705475QA (en) 2017-08-30
KR20230007545A (ko) 2023-01-12
EP4286011A3 (en) 2024-02-14
CN118667012A (zh) 2024-09-20
JP7224382B2 (ja) 2023-02-17
CN118562003A (zh) 2024-08-30
CN113384693B (zh) 2025-07-04
SI3250610T1 (sl) 2023-11-30
CN118638230A (zh) 2024-09-13
KR20170109020A (ko) 2017-09-27
DK3250610T3 (da) 2023-10-30
SMT202300365T1 (it) 2023-11-13
US20240158508A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
AU2022201145B2 (en) FcRn antibodies and methods of use thereof
US20230049725A1 (en) FcRn Antibodies and Methods of Use Thereof
JP2014509325A (ja) 拮抗性ｄｒ３リガンド
CA2972822C (en) Fcrn antibodies and methods of use thereof
HK40103769A (en) Fcrn antibodies and methods of use thereof
HK1247218B (en) Fcrn antibodies and methods of use thereof
HK1247218A1 (en) Fcrn antibodies and methods of use thereof
KR20200098604A (ko) FcRn 항체 및 이의 사용 방법
BR122021007991B1 (pt) Uso de anticorpos que se ligam a fcrn humana
BR112017015287B1 (pt) Anticorpos isolados que se ligam a fcrn humano, e composição farmacêutica

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4